Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation

Article Sidebar

Global Journal of Medical and Clinical Case Reports volume10-issue1 articles
PDF HTML
Submitted: January 2, 2023
Published: Jan 25, 2023
DOI: 10.17352/2455-5282.000167
Keywords:
Essential thrombocythemia, Pruritus, Ruxolitinib

Main Article Content

Kubra Cerci
Department of Internal Medicine, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey
Pusem Patir*
Department of Hematology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey

Abstract

Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.

Downloads

Download data is not yet available.

Article Details

Cerci, K., & Patir, P. (2023). Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation. Global Journal of Medical and Clinical Case Reports, 10(1), 001–002. https://doi.org/10.17352/2455-5282.000167
Case Studies

Copyright (c) 2023 Cerci K, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L]. PMID: 23071245; PMCID: PMC4872304.

Gugliotta L, Papayannidis C, Piccin A. Hydroxyurea treatment in 1075 patients with essential thrombocythemia and occurrence of extra-hematological adverse events: a preliminary report of the Registro Italiano Trombocitemia (RIT). Blood (ASH Annual Meeting Abstracts) 2010; 116: 1973. https://doi.org/10.1182/blood.V116.21.1973.1973

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028. PMID: 20843246; PMCID: PMC5187954.

Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, Wisch N, Xu M. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009 Jun 4;113(23):5942-50. doi: 10.1182/blood-2008-09-179416. Epub 2009 Feb 4. PMID: 19196660.

Weisshaar E, Apfelbacher C, Jäger G, Zimmermann E, Bruckner T, Diepgen TL, Gollnick H. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol. 2006 Nov;155(5):957-64. doi: 10.1111/j.1365-2133.2006.07430.x. PMID: 17034525.

Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006 Dec;17(8):528-44. doi: 10.1080/09537100600758677. PMID: 17127481.